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Abstract: Juvenile idiopathic arthritis (JIA) is the most common childhood rheumatic disease. The
development of associated uveitis represents a significant risk for serious complications, including
permanent loss of vision. Initiation of early treatment is important for controlling JIA-uveitis, but the
disease can appear asymptomatically, making frequent screening procedures necessary for patients
at risk. As our understanding of pathogenic drivers is currently incomplete, it is difficult to assess
which JIA patients are at risk of developing uveitis. Identification of specific risk factors for JIA-
associated uveitis is an important field of research, and in this review, we highlight the genomic,
transcriptomic, and proteomic factors identified as potential uveitis risk factors in JIA, and discuss
therapeutic strategies.
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1. Background
Juvenile idiopathic arthritis (JIA), the most common chronic rheumatic disease in
children, has seven sub-forms with variable clinical presentation, disease course, and
associated outcomes [1]. Inflammation of the uvea, the pigmented middle layer of the
eye comprised of the iris, ciliary body, and choroid, is the most frequent extra-articular
manifestation of JIA. Uveitis is classified based on the affected ocular compartment (anterior,
intermediate, posterior, or panuveitis) (Figure 1) and the temporal pattern of inflammation
(acute, subacute, chronic, or recurrent), with the chronic anterior form being predominant
in children with JIA-associated uveitis. While, in most cases, JIA precedes the development
of uveitis, a minority of patients develop uveitis before the onset of JIA. Though frequently
asymptomatic at onset, JIA-associated uveitis can lead to severe complications, including
permanent loss of vision, especially if left untreated [2]. This highlights the urgent need
for early detection and initiation of treatment. While the risk of developing uveitis varies
between sub-forms of JIA, early diagnosis and treatment are complicated by the current
lack of predictive markers for the development of uveitis in individual JIA patients.
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Figure 1. Anatomy of the eye. Cross-section of the human eye with major anatomical features high-
lighted. 
2. Epidemiology 
The prevalence of JIA in developed countries is estimated to range between 16–150 
per 100,000 [1,3]. The proportion of JIA patients developing uveitis is up to 30% of indi-
viduals positive for antinuclear antibodies (ANA) [4], and 10–20% across all sub-forms of 
JIA [2,5–14] (Table 1). While most studies have been performed in primarily White Cau-
casian cohorts in Western countries, the prevalence of JIA-associated uveitis appears to 
differ significantly between geographical regions. The highest prevalence is reported in 
Northern (19.1%) and Southern Europe (18.8%), the lowest in and Latin America (6.4%), 
Africa, the Middle East (5.9%), and Southeast Asia (5.0%) [15]. A recent study from Japan 
reported a uveitis prevalence of 6.1% among JIA patients [16]. 
Table 1. Juvenile idiopathic arthritis (JIA) and relative risk of uveitis. 
Type of JIA Sex Ratio (F:M) Age of Uveitis  Onset 
Uveitis 
Risk Type of Uveitis 
Systemic arthritis 1:1 N/A Low N/A 
Oligoarthritis (persistent) 3:1 Early childhood 10–20% Chronic asymptomatic 
Oligoarthritis (extended) 3:1 Early childhood 20–30% Chronic asymptomatic 
Polyarthritis (RF-) 3:1 Early childhood 10–20% Chronic asymptomatic 
Polyarthritis (RF+) 4:1 N/A Low N/A 
Psoriatic arthritis 2:1 




or acute symptomatic 
Enthesitis related arthritis 1:4 School-age 5–20% Acute symptomatic 
Approximate numbers estimated from [5,6,9,10,14,16–20]. RF, rheumatoid factor. 
3. Pathophysiology and Systemic Risk Factors 
Despite the largely unknown etiology of JIA-associated uveitis [21], several risk fac-
tors have been suggested based on demographic and clinical features. These include gen-
der, age at disease onset, and sub-type of JIA+ANA positivity [22]. A young age signifi-
cantly reduced visual acuity (<0.3) at diagnosis, low intraocular pressure, and sequence of 
disease events (uveitis before JIA onset) [23,24], and sub-form of JIA also define disease 
outcomes. Presenting evidence of ongoing disease such as cataracts, synechiae, increased 
intraocular pressure are characteristics of poor outcomes or ocular damage. 
  
Figure 1. Anatomy of the eye. Cross-section of the human eye with major anatomical
features highlighted.
2. Epidemiology
The prevalence of JIA in dev loped countries s estimated o range betwe n 16–150 per
100,00 [1,3]. The propo tion of JIA patients developing uveitis is up to 30% of indivi -
uals po itive for antinuclear antibodies (ANA) [4], and 10–20% across all sub-forms of
JIA [2,5–14] (Table 1). While most studies have be n performed in primarily White Cau-
casian cohorts in Western countries, the prevalence of JIA-as ociated uveitis ap ears to
dif er significantly betwe n geographical regions. The highest prevalence is reported in
Northern (19.1%) and Southern Europe (18.8%), the lowest in and Latin America (6.4%),
Africa, the Middle East (5.9%), and Southeast Asia (5.0%) [15]. A recent study from Japan
reported a uveitis prevalence of 6.1% among JIA patients [16].
Table 1. Juvenile idiopathic arthritis (JIA) and relative risk of uveitis.
Type of JIA Sex Ratio (F:M) Age of UveitisOnset Uveitis Risk Type of Uveitis
Systemic arthritis 1:1 N/A Lo /A
Oligoarthritis




(extended) 3:1 Early childhood 20–30%
Chronic
asymptomatic
Polyarthritis (RF-) 3:1 Early c ildhood 10–20% Chronicasymptomatic
Polyarthritis (RF+) 4:1 N/A Low N/A






arthritis 1:4 School-age 5–20%
Acute
symptomatic
Approximate numbers estimated from [5,6,9,10,14,16–20]. RF, rheumatoid factor.
3. Pathophysiology and Systemic Risk Factors
Despite the largely unknown etiology of JIA-associated uveitis [21], several risk factors
have been suggested based on demographic and clinical features. These include gender,
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age at disease onset, and sub-type of JIA+ANA positivity [22]. A young age significantly
reduced visual acuity (<0.3) at diagnosis, low intraocular pressure, and sequence of disease
events (uveitis before JIA onset) [23,24], and sub-form of JIA also define disease outcomes.
Presenting evidence of ongoing disease such as cataracts, synechiae, increased intraocular
pressure are characteristics of poor outcomes or ocular damage.
3.1. Demographic Risk Factors
Girls, as compared to boys, more frequently develop JIA-associated uveitis. However,
as this is in line with the proportion of patients with JIA, it should not be considered an
independent risk factor [2,10,14,19,25,26]. Furthermore, age at disease onset is linked to
risk. In patients diagnosed with JIA at an early age (≤6 years old), the risk of developing
uveitis is notably increased [11,16,27,28], and patients with oligoarticular (as compared to
polyarticular) arthritis more frequently develop uveitis [11,19,25,29–33]. As the highest risk
for the development of uveitis (approximately 30%) exists in the group of ANA positive
oligoarticular JIA patients, approximately 80% of who are girls, all the aforementioned
factors may be linked.
Ethnicity may affect the risk of developing JIA-associated uveitis. African Ameri-
can JIA patients develop uveitis less frequently when compared to non-Hispanic White
Caucasian patients [5]. However, other studies in multi-ethnic cohorts have not found
significant differences in relation to uveitis risk between ethnicities [19].
Associations with female sex, young age, and ethnicity suggest genetic factors as
underlying or cause. As uveitis-associated genetic variants are manifold and complex, they
will be discussed specifically below.
3.2. Immune Cells and Serum Proteins
The presence of anti-ocular protein autoantibodies has been reported in sera of patients
with JIA-associated uveitis [34–37]. Notably, ANA can also be present in JIA patients
without uveitis or healthy individuals, but more commonly occur in uveitis patients,
particularly when directed against iris proteins. While it is unknown whether antibody
positivity is a cause or result of ocular damage, it may certainly contribute to prolonged
local inflammation. A correlation between the presence of serum antibodies binding iris
and ciliary body proteins and ocular complications in JIA-associated uveitis has been
described [37], which may be used as a future risk stratification tool.
In a small study in 18 children with JIA-associated uveitis, utilizing immunoflow
to quantify T-cell surface markers and intracellular cytokines, an increase in the ratio
between type 1 T helper cells and type 2 T helper cells (Th1/Th2 ratio) was seen in patients
compared with healthy controls [38]. Mean levels were elevated in both JIA-associated
and idiopathic anterior uveitis patients, although differences did not reach a significance
level. Th1 polarization is believed to result in a predisposition to the development of
autoimmune/inflammatory disease and animal models of uveitis have suggested that
uveitis is predominantly a Th1/Th17-mediated condition [39,40]. While the study did not
detect significant differences in Th17 producing cells between the inflammatory patient
groups, Th17 cells across inflammatory disorders were elevated as compared to healthy
controls both regarding the quantity of CD4+/IL17+ cells and mean fluorescence intensity
of IL-17 protein.
In a study that analyzed molecular phenotypes of circulating immune cells in patients
with JIA-associated uveitis compared to healthy controls or patients with uveitis associated
with adult-onset axial spondyloarthritis (SpA), JIA-uveitis patients showed significantly
increased numbers of CD56+ monocytes and CCR7+ dendritic cells (DCs) [41]. While none
of the uveitis groups exhibited significant differences in the composition of main monocyte
populations (classical, intermediate, or non-classical), JIA patients had increased CD56+
classical monocytes as compared to both healthy controls and SpA patients. Indeed, this
monocyte population was reduced for SpA patients, which may be associated with the
presence of HLA-B27 positivity (18% vs. 95%). Regarding DCs, in line with previous
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research showing increased expression of the chemokine receptor CCR7 in rheumatoid
arthritis [42], JIA-associated uveitis patients also showed an elevated frequency of CCR7-
positive myeloid DCs, which may contribute to their recruitment to tissues affected.
Recently, non-biased proteomic and transcriptomic analyses of iris biopsies, aque-
ous humor (AqH), and serum from JIA-associated uveitis patients revealed differential
expression of 136 genes and 56 proteins as compared to patients with primary open-angle
glaucoma (POAG) [43], with multiple B-cell related genes upregulated in the uveitis group.
These include CD19, CD20, CD27, CD138, and MZB1. Increased concentrations of B-cell
survival factors BAFF, APRIL, and IL-6 in the AqH further underscored the probable role
of B-cells in the pathogenesis of JIA-associated uveitis. As neither BAFF nor APRIL was
found elevated in serum samples, this effect may not be systemic.
Calcium-binding S100 proteins are a family of low molecular weight proteins secreted
by a wide variety of cells. Elevated levels of S100 proteins have previously been described
in multiple systemic inflammatory diseases in both children and adults [44,45]. S100A8/A9
heterodimers and S100A12 are elevated in both serum and AqH in JIA-associated uveitis
patients as compared to JIA patients without uveitis [46]. Furthermore, serum levels of
both S100A8/A9 and S100A12 correlate with uveitis activity. As elevated AqH levels of
S100A8/A9 were also reported in idiopathic anterior uveitis and herpetic anterior uveitis,
their presence does not appear to be specific for JIA-associated uveitis. S100A8/A9 and
S100A12 serum levels were elevated not only in patients with active joint inflammation but
also patients with inactive joint inflammation but active uveitis, indicating that this may
be a systemic marker of ongoing immune response rather than a specific disease group.
Mechanistically, secreted S100 proteins are capable of activating TLR4 [47] and TLR2 [48]
signaling, as well as the receptor for advanced glycation end-products [48], thereby acti-
vating the innate immune response and production of pro-inflammatory cytokines and
chemokines in phagocytes and monocytes.
3.3. Environmental Factors
Lastly, environmental factors may be associated with an increased risk of uveitis in
JIA [49]. Vitamin D deficiency is associated with multiple autoimmune/inflammatory
diseases [50]. Whether an association between low vitamin D levels and the incidence of
JIA exists is not clear [51], but data from a German cohort suggests vitamin D deficiency
in JIA patients to be associated with higher disease activity and increased risk for the
development of JIA associated uveitis [52]. As sun exposure affects vitamin D levels [53],
low vitamin D may also contribute to the aforementioned differences in uveitis prevalence
between geographic regions with Northern countries having the highest uveitis rates
among JIA patients.
4. Genetic Factors
In view of the permanent nature of our genetic makeup, the identification of variants
that confer elevated risk for the development of uveitis in JIA is highly significant and may
be utilized as predictive markers even before disease onset. Demographic and geographic
associations suggest genetic variants to contribute to disease risk and expression. Reports
of familial clusters exist [54–59], but as these are rare, it remains unclear whether they
support a role for genetic influence in JIA-associated uveitis pathology.
4.1. Human Leukocyte Antigen (HLA)
In keeping with many other autoimmune/inflammatory diseases, polymorphisms
in the human leukocyte antigen (HLA) region have been associated with uveitis in JIA.
Genome-wide association studies (GWAS) investigating 522 JIA patients, 192 of which
experienced uveitis [60], showed that the presence of a serine amino acid residue at position
11 of the YST motif, comprised of tyrosine (Y), serine (S), and threonine (T), of the HLA–
DRβ1 peptide-binding groove associates with increased risk for the development of uveitis
in girls. The HLADRB1 gene encodes for the beta-subunit of HLA-DR, a heterodimeric
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MHC class II cell surface receptor expressed primarily on antigen-presenting cells. Thus,
modifications in the peptide-binding groove may affect MHC class II antigen presentation.
Interestingly, as HLA-expression on T-cells is considered a marker of T-cell activation,
increased expression of HLA-on T-cells has been linked with multiple autoimmune dis-
eases. For example, the proportion of HLA-positive CD8 T-cells has been shown to reflect
disease activity in SLE [61], and in Kawasaki disease, increased T-cell HLA-expression is
associated with resistance to administration of intravenous immunoglobulin [62]. Another
study in Japanese JIA patients reported polymorphisms in HLA-A and HLA-DRβ1 to be
associated with risk of uveitis in a cohort of 106 patients (67 with polyarthritis and 39 with
oligoarthritis) compared with 678 healthy controls [63].
In enthesitis-related arthritis (ERA) JIA, a type of uveitis characterized by acute onset
and conjunctival injection, pain, and photophobia occurs in approximately 10% of patients
within 6 months of disease onset [64]. This contrasts with uveitis in other forms of JIA,
which is often asymptomatic. ERA JIA is defined as arthritis and enthesitis, or arthritis
or enthesitis with at least two of the following: the presence of or a history of sacroiliac
joint tenderness and/or inflammatory lumbosacral pain, HLA-B27 positivity, the onset
of arthritis in a male over 6 years of age, acute (symptomatic) anterior uveitis, or history
of HLA-B27-associated disease [65]. HLA-B27 positive ERA JIA patients are at increased
risk compared with HLA-B27 negative [20,66]. Uveitis is also a common feature of adult-
onset SpA where the vast majority of patients are HLA-B27 positive [67], underscoring the
aforementioned potential role for HLA-B27 in uveitis development.
4.2. Non-HLA Genes
Studies investigating non-HLA genes that may confer risk of JIA-associated uveitis
delivered some conflicting results. Sequencing of the promoter region of IL1A in White
Norwegian JIA patients delivered an association of a single nucleotide polymorphism
(SNP) that was particularly strong in uveitis patients [68]. However, this was not replicated
in other studies in White Caucasian patients in the UK [69,70].
Retrospective analysis of sequence variants in six genes (PTPN22, STAT4, TRAF1/C5 lo-
cus, TGFB, TNFAIP3, and C12orf30) associated with JIA or other autoimmune/inflammatory
conditions did not reveal association with uveitis across all JIA sub-forms [71]. However,
the TRAF1/C5 AA allele at chr9:120942809 (GRCh38.p12; rs10818488) which is in strong link-
age disequilibrium with an SNP at chr9:120927961 (GRCh38.p12; rs3761847) in Caucasian
and Asian populations [72], while just missing significance level (p = 0.06) in oligoarticular
and polyarticular RF-negative JIA, is associated with increased uveitis risk in ANA positive
oligoarticular and polyarticular JIA patients. The TRAF1/C5 variants are located near genes
encoding for the complement component 5 and the TNF-receptor associated factor 1, a
negative regulator of the TNF pathway, underscoring the role of TNF signaling in JIA
associated uveitis [73].
Investigation of 17 non-HLA variants associated with JIA in a multicenter study cohort
of patients from the Nordic countries identified a polymorphism in the gene encoding the
V-set domain-containing T-cell activation inhibitor-1 (VTCN1), also known as B7-H4, to
be associated with an increased risk of uveitis [74]. While the confidence interval of the
odds ratio was broad (95% CI: 1.01–12.14), this is an interesting finding, as B7-H4 acts as a
negative regulator of the T-cell immune response [75].
5. Laboratory Biomarkers
The detection and/or quantification of biological markers associating with the pres-
ence of uveitis or disease outcomes, such as proteins or immune cell composition in the
blood or other tissue, may allow for risk stratification and informed treatment. Several
potential markers have been suggested and evaluated in JIA-associated uveitis, with some
already used in clinical practice (Table 2).
Children 2021, 8, 646 6 of 15
Table 2. Potential biomarkers in JIA-associated uveitis.
Risk Factor Tissue Status inJIA-Uveitis
Comparator
Group Reference
ANA Blood Higher proportionpositive JIA
[2,4,10,11,14,16,19,
25,26,28,76–78]









BAFF AqH Increased POAG [43]
APRIL AqH Increased POAG [43]
IL-6 AqH Increased POAG [43]
















S100A8/A9 AqH/Serum Increased JIA [46]
S100A12 AqH/Serum Increased JIA [46]
SEMA3G Tears Increased Idiopathic uveitis [87]
TIMP1 Tears Increased Idiopathic uveitis [87]
HEXB Tears Increased Idiopathic uveitis [87]
ERN1 Tears Increased Idiopathic uveitis [87]
SAA1 Tears Increased Idiopathic uveitis [87]
sCD14 Tears Increased Idiopathic uveitis [87]
S100A8 Tears Increased Idiopathic uveitis [87]
S100A9 Tears Reduced Idiopathic uveitis [87]
LAP3 Tears Reduced Idiopathic uveitis [87]
TTR Tears Reduced Idiopathic uveitis [87]
MIF Tears Reduced Idiopathic uveitis [87]
ANA, anti-nuclear antibodies; ESR, erythrocyte sedimentation rate; BAFF, B-cell activating factor; APRIL,
a proliferation-inducing ligand; OPG, osteoprotegerin; LAP, latency-associated peptide; TTR, transthyretin;
SEMA3G, semaphorin 3G; TIMP1, tissue inhibitor of metalloproteinases 1; HEXB, hexosaminidase subunit beta;
ERN1, endoplasmic reticulum to nucleus signaling 1; SAA1, serum amyloid A1; sCD14, soluble CD14; LAP3,
latency-associated peptide; MIF, macrophage migration inhibitory factor; AqH, aqueous humor; POAG, primary
open-angle glaucoma.
5.1. Anti-Nuclear Antibodies (ANAs)
The most consistent current predictor of uveitis development in JIA is the presence
of ANAs. Several studies independently concluded that ANA-positive JIA patients ex-
hibit an increased risk for the development of uveitis [2,4,10,11,14,16,19,25,26,28,76–78].
Antinuclear antibodies bind DNA, RNA, nucleosomes, and/or nuclear proteins, and are
implicated in the pathophysiology of several autoimmune/inflammatory conditions and
therefore routinely tested in clinical settings. The exact mechanistic link between ANAs
and uveitis is not known. However, it is noteworthy that B-cells and fully differentiated
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plasma cells are characteristic of the inflammatory ocular cellular infiltrate in JIA-associated
uveitis [88–92]. This, and the high prevalence of ANA positivity, suggest a role of B-cell
dysregulation in disease pathophysiology.
5.2. Rheumatoid Factor (RF)
Another commonly tested and observed autoantibody is the rheumatoid factor (RF).
Notably, RF positivity associates with a relatively low risk of uveitis development [22].
Thus, RF has previously been discussed as having “protective” effects [5]. However,
if uveitis occurs in individuals testing positive for RF, it shows more severe clinical
courses [93]. The less favorable ocular outcome in RF-positive JIA patients with uveitis
may rather reflect reduced differences in the pathophysiology and associated uveitis risk
of different JIA sub-forms, rather than having a protective effect as an autoantibody.
5.3. Erythrocyte Sedimentation Rate (ESR)
Accelerated erythrocyte sedimentation rates (ESR) have been reported in JIA-associated
uveitis patients [14,79–84]. As ESR is routinely measured during standard blood tests in
JIA, this could potentially provide valuable and cost-effective insight into the risk of devel-
oping uveitis. Elevated ESR typically reflects the increased activity of the immune system,
which in the context of autoimmune disease could indicate high levels of inflammation.
Specifically, for uveitis, a hyperactive immune system may predispose ocular infiltration
of reactive immune cells. While this may suggest that ESR would be a useful tool for
evaluating the baseline risk of developing uveitis in JIA at the time of diagnosis, it should
be noted that normalization of ESR following successful treatment and resolution of inflam-
mation is typically delayed [94]. This makes it less useful for ongoing disease monitoring in
response to treatment. Furthermore, elevated ESR may be linked to a number of unrelated
factors, such as plasma albumin concentration and patient red blood cell characteristics
present in hematological disorders, which are affected by demographic factors (e.g., age,
sex). These factors limit the practical usability of the ESR in JIA-associated uveitis disease
monitoring [95].
5.4. Ocular Proteins
Multiplex analysis of 51 inflammatory mediators in AqH and serum samples from
JIA-associated uveitis patients compared with chronic anterior uveitis without arthritis,
noninfectious idiopathic uveitis and healthy controls identified reduced IL-29 in AqH as a
specific marker for JIA-uveitis [85]. Furthermore, AqH levels of osteoprotegerin (OPG) and
latency-associated peptide (LAP) were elevated in comparison with the idiopathic uveitis
and healthy control groups. When analyzed for differences in serum samples, IL-29 could
not be compared as it was not detected in most samples, while OPG and LAP did not show
differences between groups. IL-29 (also known as interferon-λ1) is a proinflammatory type
III interferon that tightens the blood-brain barrier in response to West Nile infection [96],
and could potentially play a similar role in the maintenance of the immune-privileged status
of the eye via the blood-retina barrier function. However, elevated levels of interferon-λ
are also seen in the retinae of age-related macular degeneration patients, which there
provides a signal for homing of neutrophils into the retina by upregulating neutrophil
LCN-2 through the STAT1 pathway [97].
Surface-enhanced laser desorption/ionization (SELDI) time of flight (ToF) mass spec-
trometry analysis of paired serum and AqH samples in children with uveitis delivered
distinct differences in AqH proteins between JIA-associated uveitis and other forms of
childhood uveitis and healthy controls [86]. The study identified transthyretin (TTR) as a
potential local marker for JIA-associated uveitis, as AqH levels were increased in JIA and
silent chronic anterior uveitis, while the protein was not detected in serum. Ocular TTR is
abundantly produced and apically secreted by the retinal pigment epithelium in a polar-
ized manner [98]. It has amyloidogenic properties and has been found in drusen [99], the
extracellular subretinal deposits frequently observed in age-related macular degeneration.
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Because of the relative difficulty and invasiveness of sampling AqH, tear collection
has been suggested for protein analysis in the context of uveitis. In a pilot study on three
children with JIA-uveitis, elevated levels of proteins associated with inflammatory arthritis
(SEMA3G, TIMP1, HEXB, ERN1, and SAA1) was found, in addition to elevated levels
of sCD14, S100A8, and SAA1, but reduced levels of S100A9, LAP3, TTR, and MIF [87].
Previously, tear levels of IL-1RA, IL-8, fractalkine, IP-10, VEGF, and TGF-β2 had been
shown to be elevated in uveitis [100], although this study encompassed multiple diverse
forms of uveitis and not specifically JIA-associated uveitis.
6. Treatment
Management of JIA-uveitis encompasses multiple aspects, including screening, joint
pediatric rheumatology and ophthalmology clinics, and multidisciplinary care. As evidence-
based guidelines are relatively sparse, regimens are largely based on physicians’ experience.
Initiatives to provide international expert consensus opinions on diagnosis and treatment
of JIA-uveitis, such as those developed by the Single Hub and Access point for pediatric
Rheumatology in Europe (SHARE) initiative [101] have been developed to identify best
practices in treatment and care.
Regarding pharmaceutical interventions, first-line treatment strategies for JIA-associated
uveitis include topical glucocorticoids, and in the case of synechiae, mydriatic eye drops to
prevent an increase in intraocular pressure and cataract development. If topical treatment
fails to induce stable remission, systemic treatments are added, which may include corti-
costeroids, disease-modifying antirheumatic drugs (DMARDs), and biopharmaceutical
agents [102–105]. Regarding the use of corticosteroids, paucity of evidence underpins
the most effective route of administration (oral vs. intravenous), dosing, and treatment
duration. A recent retrospective study suggested intravenous methylprednisolone pulse
treatment to be effective in limiting inflammatory activity in uveitis at diagnosis and during
disease flares, even when already treated with second-line agents [106]. However, based
on small case numbers, the study was unable to draw reliable conclusions on how many
pulses (namely, one versus three or more in monthly intervals) may be necessary to induce
stable remission [106].
If corticosteroid treatment fails or flares occur after their discontinuation, several
DMARDs may be used to achieve or maintain remission. Methotrexate is the standard first-
line DMARD used and is generally considered more effective as compared to azathioprine
or mycophenolate mofetil [107,108]. Although T-cell inhibition mediated via cyclosporine
has been shown to be effective against idiopathic uveitis [109], the drug was found to
be of limited efficacy in JIA-associated uveitis [110], suggesting different or additional
mechanisms or immune cell involvement for disease progression.
In patients with failing or with insufficient response to DMARDs, biopharmaceutical
drugs will be used, usually targeting TNF and IL-6 pathways [104]. The SYCAMORE
trial [111] demonstrated the significant benefit of anti-TNF treatment (adalimumab) in
patients failing on methotrexate, and the ADJUVITE trial [112] was in favor of using
adalimumab in patients with early-onset, chronic anterior uveitis, which is in most cases
associated with JIA, in case of inadequate response to topical therapy and methotrexate.
The APTITUDE trial [113] showed mixed results in using anti-IL6 treatment (tocilizumab).
Although the endpoint was not met to determine evidence for a phase III trial, one-third of
participants had a two-step improvement in uveitis assessment at week 12, and three of
four participants had complete resolution of cystoid macular edema. Notably, it should be
noted that the APTITUDE trial was focused on patients refractory to anti-TNF treatment.
Tocilizumab may therefore provide a therapeutic option in some children with uveitis
refractory to anti-TNF drugs, given the absence of other treatment options. Additional
and/or future candidates for application in JIA-associated uveitis currently being evaluated
include small-molecule Janus kinase (JAK) inhibitors, and biopharmaceutical drugs, such as
IL-17 inhibitors, B-cell depletion (e.g., through anti-CD20 antibodies), and T-cell inhibition
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(e.g., through CTLA-4) [114]. For future trials and basic science studies, ANA positive
chronic anterior uveitis should be considered the same disease as JIA-associated uveitis.
A central challenge in the therapeutic management of JIA-associated uveitis concerns
surgical management of complications, e.g., cataracts and glaucoma, where adequate im-
munosuppression is essential with no tolerance for even mildly active ocular inflammation.
Possible postoperative (and inflammation-associated) complications include synechiae,
cyclitic membrane, postoperative glaucoma, and macular edema, and consequently, the
therapeutic approach must also seek to improve outcomes in these patients [115]. Future
care will involve close interdisciplinary collaboration between pediatricians and immunol-
ogists to improve outcomes.
Currently, a central problem with determining the optimal treatment strategy for JIA-
associated uveitis is that predictive biomarkers for treatment response (or non-response)
are lacking. While the strong benefits of early detection of uveitis and initiation of
treatment are well established, valuable time can be lost due to selecting a sub-optimal
drug. Identification of reliable biomarkers will help to inform treatment strategy and
should therefore be considered a high priority in ongoing research. These issues are
currently being addressed by the MRC-funded UK-wide CLUSTER Consortium (https:
//www.clusterconsortium.org.uk accessed on 21 June 2021) and other international collab-
orative initiatives.
7. Conclusions and Future Directions
JIA is the most common childhood rheumatic disease. Associated uveitis can result in
severe associated complications. The risk of developing uveitis in JIA has to date mainly
been evaluated in relation to demographic and clinical factors. Recent research efforts
have increasingly employed molecular proteomic and cellular phenotyping tools with the
aim of identifying patient-specific markers that modulate the overall risk. As several new
therapeutics are considered as options for clinical use, biomarker discovery studies are
of critical importance for future ability to determine optimal strategies for personalized
medicine. Although an ideal biomarker would be a single factor that is highly specific
and sensitive, more realistic outcomes of these studies would be multifactorial panels of
biomarkers that combined can inform individual risk of developing uveitis in JIA, as well
as treatment response for patients with diagnosed JIA-associated uveitis.
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Search Strategy and Review Criteria: We searched the MEDLINE database via PubMed for relevant
published articles in English language published before April 2021. Search terms used were “juvenile
idiopathic arthritis” and “uveitis”, or a number of synonyms to these terms, including “juvenile
rheumatoid arthritis”, “juvenile chronic arthritis”, “juvenile arthritis”, “jia”, “iritis”, and “iridocycli-
tis”. The reference lists of selected articles were also reviewed for additional relevant papers. All
articles considered relevant were taken into account, with an emphasis for articles published in the
last 5 years.
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